Drugs / Epalrestat
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07557914 | Oct 2026 → Feb 2029 expected | diabetes mellitus, hepatocellular carcinoma | Haibo Shao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05777226 | Apr 2023 → Apr 2026 | Charcot-Marie-Tooth disease | The Third Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT03244358 | Mar 2017 → Dec 2020 | triple-negative breast carcinoma | Sun Yat-sen University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT04925960 | Nov 2022 → Feb 2025 | PMM2-congenital disorder of glycosylation | Maggie's Pearl, LLC | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05184049 | Jan 2022 → Oct 2023 | diabetes mellitus | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06201611 Comparator | Nov 2024 → Dec 2025 overdue | diabetic polyneuropathy | St. John's Research Institute | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-02-01 | Ono Pharmaceutical Co., Ltd. | ONO Announces Transfer of the Manufacturing and Marketing Approval Authorization for Kinedak Tablets to Alfresa Pharma Corporation ono-pharma.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epalrestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05777226 ↗ |
| Known as | Aldonil | ChEMBL registry synonym — accepted as the source's own label CHEMBL56337 ↗ |
| Known as | Aldorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL56337 ↗ |
| Known as | Kinedak | ChEMBL registry synonym — accepted as the source's own label CHEMBL56337 ↗ |
| Known as | Tanglin | ChEMBL registry synonym — accepted as the source's own label CHEMBL56337 ↗ |
| Action | Inhibit | “aldose reductase inhibitor (ARI)” NCT04925960 ↗1“Aldose reductase inhibitor” CHEMBL56337 ↗ |
| Modality | Small molecule | — CHEMBL56337 ↗ |
| Route | Oral | “Epalrestat will be administered orally” NCT04925960 ↗ |
| Target | AKR1B1 | “Aldose reductase inhibitor” CHEMBL56337 ↗ |